Stock JUNO THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Juno Therapeutics Inc Stock

Equities

US48205A1097

Biotechnology & Medical Research

Chart Juno Therapeutics Inc

Dynamic Chart

Latest news about Juno Therapeutics Inc

Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide RE
Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide RE
Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid RE
Gilead Sciences : Sangamo in $3 billion gene-editing deal with Gilead RE
Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom RE
Stocks hit record as senators reach deal to end shutdown RE
Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion RE
Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion RE
Novartis : FDA panel backs Novartis' pioneering new cancer gene therapy RE
Juno Therapeutics : Yahoo says about 32 million accounts accessed using 'forged cookies' RE
Juno Therapeutics : Yahoo says about 32 million accounts accessed using 'forged cookies' RE
Juno Therapeutics : Shares of Juno Therapeutics jump after FDA removes clinical hold on cancer drug trial RE
Celgene : Wall Street lauds Celgene's $7.2 billion Receptos buy RE
Celgene : to buy Receptos for $7.2 billion; gains promising drug RE
More news

Press releases Juno Therapeutics Inc

Juno Therapeutics : Celgene Receives Antitrust Clearance for Juno Acquisition BU
WeissLaw LLP : Investigates Juno Therapeutics Inc. Acquisition PR
JUNO THERAPEUTICS, INC. Former SEC Attorney Willie Briscoe Believes the Acquisition by Celgene Corporation May be Unfair to Shareholders BU
Celgene Corporation : to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy BU
JUNO THERAPEUTICS INVESTIGATION by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. - JUNO BU
More press releases

News in other languages on Juno Therapeutics Inc

Ablynx : Sanofi s'offre une nouvelle biotech en achetant Ablynx 3,9 milliards d'euros
Original-Research: Medigene AG (von EQUITS GmbH): Kaufen
Apple : Wall Street finit en hausse, accord sur le "shutdown"
BOURSE : Wall Street finit à des records après l'accord au Sénat mettant fin au "shutdown"
Barclays : Les Bourses européennes clôturent en hausse, le M&A éclipse le "shutdown"
More news

Managers and Directors - Juno Therapeutics Inc

Managers TitleAgeSince
Nicole Keith IRC
 Investor Relations Contact - 15-06-30
Jonathan Biller TRE
 Treasurer 61 -
Katherine Reynolds Kelly SEC
 Corporate Secretary 48 -
Members of the board TitleAgeSince
Mark Alles BRD
 Director/Board Member 64 -
Peter Kellogg BRD
 Director/Board Member 67 -
More insiders

Company Profile

More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.71B
ARGENX SE Stock argenx SE
+1.69% 22.02B
BIONTECH SE Stock BioNTech SE
-17.37% 20.9B
GENMAB A/S Stock Genmab A/S
-9.30% 17.85B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 15.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.86B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.04B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. Stock